• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Inovio names new chief medical officer

June 27, 2022 By Sean Whooley

Inovio PharmaceuticalsInovio (Nasdaq:INO) announced today that it appointed Dr. Michael Sumner as its new chief medical officer (CMO).

Sumner will oversee Inovio’s clinical-stage pipeline of DNA medicines, global clinical development, clinical operations and biostatistics efforts, along with regulatory affairs, pharmacovigilance and medical affairs.

He will also serve on the company’s executive leadership team and report to President and CEO Dr. Jacqueline Shea in his role at the Plymouth Meeting, Pennsylvania-based developer of vaccines and vaccine delivery technology.

“Inovio is pleased to welcome Dr. Sumner to Inovio,” Shea said in a news release. “An industry veteran and a member of the Royal College of Physicians, Dr. Sumner’s clinical development and medical affairs expertise and track record of helping guide companies through regulatory approval and commercialization make him an important addition to the Inovio team.”

Sumner has served as CMO at Orexo AB since 2013, having previously held a range of European- and U.S.-based leadership roles at Novartis, Aventis Behring, Novo Nordisk and Shire Pharmaceuticals.

He holds more than 25 years of experience in the pharmaceutical, medical and clinical fields, driving numerous late-stage produce approvals and supporting successful commercial products on a global basis across several therapeutic areas, Inovio said.

“I am pleased to join Inovio as CMO and look forward to working with the team to unlock the power of the DNA medicines platform to address unmet medical need,” Sumner said.

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Oncology, Personnel, Pharmaceuticals Tagged With: Inovio Pharmaceuticals, Personnel, Personnel Moves

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS